Market Closed - Nasdaq 04:00:00 2024-06-20 pm EDT 5-day change 1st Jan Change
19.18 USD -1.36% Intraday chart for NovoCure Limited -10.90% +28.43%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating MT
Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial CI
Novocure Releases Topline Efficacy and Safety Data from the TIGER Study Investigating the Use of Tumor Treating Fields Therapy in the Treatment of Patients with Newly Diagnosed Glioblastoma in Germany CI
NovoCure Shares Steady After Reporting Narrower Q1 Loss, Higher Revenue MT
BioPharma Credit Enters $400 Million Loan Agreement with Novocure Luxembourg MT
BioPharma Credit agrees USD400 million loan for oncology firm Novacure AN
Transcript : NovoCure Limited, Q1 2024 Earnings Call, May 02, 2024
Earnings Flash (NVCR) NOVOCURE Reports Q1 Revenue $138.5M, vs. Street Est of $131.5M MT
NovoCure Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Novocure Enters into New Five-Year Up to $400 Million Committed Senior Secured Credit Facility with Funds Managed by Pharmakon Advisors, LP CI
NovoCure Limited announced that it expects to receive $400 million in funding CI
NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer CI
Piper Sandler Raises NovoCure's Price Target to $28 From $25, Maintains Overweight Rating MT
NovoCure Says New Data Show TTFields' Potential Therapeutic Effects in Pancreatic Cancer MT
Wells Fargo Cuts Price Target on NovoCure to $42 From $49, Keeps Overweight Rating MT
Zai Lab, Novocure Say TTFields Therapy Delays Intracranial Progression in Non-Small Cell Lung Cancer Brain Metastases Patients MT
Sector Update: Health Care Stocks Edge Higher Pre-Bell Wednesday MT
Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data MT
Sector Update: Health Care MT
NovoCure Says Trial of Therapy for Brain Metastases From Lung Cancer Met Primary Endpoint; Shares Jump Pre-Bell MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Ahead of Fed Board Governor Waller's Speech MT
Transcript : NovoCure Limited - Special Call
Novocure's lung cancer therapy succeeds in late-stage trial RE
Evercore ISI Adjusts Price Target on NovoCure to $15 From $14, Keeps In Line Rating MT
Novocure Q4 Net Loss Widens, Revenue Rises MT
Chart NovoCure Limited
More charts
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
19.18 USD
Average target price
26.36 USD
Spread / Average Target
  1. Stock Market
  2. Equities
  3. NVCR Stock
  4. News NovoCure Limited
  5. NovoCure Shares Steady After Reporting Narrower Q1 Loss, Higher Revenue